Trial
NCT01453595
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Novartis
Condition
Renal Cancer
Intervention
BEZ235
Why stopped
Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-29